immun
rightli
regard
one
great
medic
success
past
two
hundr
year
particularli
centuri
develop
countri
decad
immun
programm
led
elimin
smallpox
polio
control
near
elimin
oncecommon
often
debilit
even
lifethreaten
diseas
measl
mump
rubella
diptheria
tetanu
despit
view
poor
rel
tradit
drug
develop
vaccin
market
estim
us
billion
fig
project
annual
growth
rate
recent
media
attent
surround
new
emerg
infect
west
nile
viru
sever
acut
respiratori
syndrom
sar
monkeypox
increas
interest
develop
new
vaccin
potenti
lethal
pathogen
ad
fear
known
unknown
pathogen
could
use
bioweapon
renew
research
interest
diseas
smallpox
anthrax
plagu
bioterror
spur
vaccin
research
although
new
concept
use
bacteria
virus
bioweapon
becom
greater
topic
convers
follow
anthrax
attack
unit
state
sinc
mani
govern
acceler
effort
develop
produc
stockpil
drug
vaccin
number
pathogen
potenti
use
bioweapon
includ
bacillu
anthraci
anthrax
clostridium
botulinum
botul
yersinia
pesti
plagu
francisella
tularensi
tularemia
variola
smallpox
hantaviru
hantaviru
pulmonari
syndrom
part
effort
presid
bush
project
bioshield
bill
invest
us
billion
next
decad
research
new
prevent
treatment
includ
privat
public
effort
unit
state
collabor
research
bodi
around
world
infecti
agent
smallpox
effect
vaccin
alreadi
exist
help
erad
diseas
global
last
known
case
smallpox
report
despit
smallpox
still
pose
signific
threat
bioweapon
highli
contagi
countri
immun
programm
ceas
result
larg
pool
unprotect
peopl
seriou
side
effect
exist
smallpox
vaccin
dryvax
wyeth
threat
new
virul
form
smallpox
mean
still
need
new
safer
version
vaccin
new
strategi
includ
use
live
attenu
vaccinia
viru
modifi
vaccinia
ankara
mvabn
bavarian
tbcmva
therion
phase
trial
altern
manufactur
vaccinia
vaccin
acambi
ccsv
dynport
phase
ii
trial
respect
sar
new
challeng
recent
outbreak
sar
remind
us
new
virul
virus
suddenli
emerg
anytim
spread
rapidli
around
globe
world
health
organ
estim
peopl
infect
sar
countri
kill
estim
peopl
although
nearli
scale
influenza
pandem
sar
remain
menac
global
public
health
especi
turn
season
diseas
follow
first
report
case
sar
late
februari
health
agenc
quickli
realiz
deal
one
typic
respiratori
virus
caus
diseas
pneumonia
flu
exampl
respiratori
syncyti
viru
influenza
viru
instead
new
virul
strain
often
associ
sever
patholog
fortun
sar
epidem
short
live
still
place
consider
strain
health
system
mani
affect
countri
threat
remain
still
great
need
sar
vaccin
prevent
loss
life
potenti
larger
scale
end
larg
number
public
privat
initi
underway
develop
sar
vaccin
exampl
nation
institut
health
merck
genvec
avant
immunotherapeut
activ
area
although
even
optimist
estim
vaccin
still
least
five
year
away
high
hurdl
set
hiv
vaccin
hunt
hiv
vaccin
arguabl
one
urgent
task
time
million
dollar
spent
tri
understand
everi
aspect
viru
role
pathogenesi
mani
antiretrovir
avail
treat
hiv
side
effect
associ
resist
issu
none
offer
cure
instead
prolong
time
onset
aid
addit
drug
exert
heavi
financi
toll
develop
countri
often
unabl
bear
hope
develop
effect
hiv
vaccin
could
help
eas
econom
burden
unfortun
hiv
like
malaria
tuberculosi
turn
tricki
develop
effect
vaccin
high
degre
antigen
variabl
exist
among
hiv
strain
exampl
recent
failur
subunit
vaccin
aidsvax
bb
vaxgen
advanc
hiv
vaccin
howev
result
dampen
research
effort
field
contrari
seen
explos
activ
past
year
present
phase
ii
iii
trial
ongo
involv
varieti
differ
strategi
includ
use
complex
subunit
vaccin
exampl
oligomer
protein
recombin
viral
vector
includ
attenu
adenoviru
canarypox
modifi
vaccinia
ankara
bcg
semliki
forest
viru
strategi
dna
vaccin
design
protect
patient
wherea
other
attempt
strengthen
immun
respons
prolong
progress
aid
market
indic
tradit
vaccin
continu
gener
major
us
billion
vaccin
sale
year
fig
although
believ
futur
growth
driven
new
vaccin
includ
improv
deliveri
mechan
exampl
medimmun
intranas
flumist
well
vaccin
emerg
diseas
pathogen
pose
threat
possibl
bioweapon
tabl
infecti
agent
hiv
present
affect
estim
million
peopl
around
globe
highlight
great
need
futur
vaccin
wherea
viru
also
shown
us
signific
difficulti
exampl
antigen
variat
must
overcom
truli
global
vaccin
develop
